PL1888031T3 - Preparaty analogu glp-1 - Google Patents
Preparaty analogu glp-1Info
- Publication number
- PL1888031T3 PL1888031T3 PL06744133T PL06744133T PL1888031T3 PL 1888031 T3 PL1888031 T3 PL 1888031T3 PL 06744133 T PL06744133 T PL 06744133T PL 06744133 T PL06744133 T PL 06744133T PL 1888031 T3 PL1888031 T3 PL 1888031T3
- Authority
- PL
- Poland
- Prior art keywords
- glp
- analogue formulations
- analogue
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2005/002217 WO2005117830A1 (en) | 2004-06-04 | 2005-06-06 | Liquid depot formulations |
PCT/GB2005/004752 WO2006075125A1 (en) | 2005-01-14 | 2005-12-09 | GnRH ANALOGUE FORMULATIONS |
PCT/GB2006/002079 WO2006131730A1 (en) | 2005-06-06 | 2006-06-06 | Glp-1 analogue formulations |
EP06744133A EP1888031B1 (en) | 2005-06-06 | 2006-06-06 | Glp-1 analogue formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1888031T3 true PL1888031T3 (pl) | 2013-04-30 |
Family
ID=36741345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06744133T PL1888031T3 (pl) | 2005-06-06 | 2006-06-06 | Preparaty analogu glp-1 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8546326B2 (pl) |
EP (1) | EP1888031B1 (pl) |
JP (1) | JP5198261B2 (pl) |
CN (1) | CN101217940B (pl) |
CA (1) | CA2609810C (pl) |
DK (1) | DK1888031T3 (pl) |
ES (1) | ES2399645T3 (pl) |
PL (1) | PL1888031T3 (pl) |
WO (1) | WO2006131730A1 (pl) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2390331C2 (ru) * | 2004-06-04 | 2010-05-27 | Камурус Аб | Жидкие депо-препараты |
ES2400034T3 (es) | 2005-01-14 | 2013-04-05 | Camurus Ab | Formulaciones bioadhesivas tópicas |
US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
US8871712B2 (en) * | 2005-01-14 | 2014-10-28 | Camurus Ab | Somatostatin analogue formulations |
CA2595385C (en) * | 2005-01-21 | 2011-01-25 | Camurus Ab | Pharmaceutical lipid compositions |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
CN101217940B (zh) | 2005-06-06 | 2013-03-27 | 卡穆鲁斯公司 | Glp-1类似物制剂 |
EP3095456A1 (en) | 2005-11-04 | 2016-11-23 | Glaxosmithkline LLC | Methods for administering hypoglycemic agents |
CA2670821C (en) | 2006-08-09 | 2012-05-15 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
US20080234376A1 (en) * | 2007-03-21 | 2008-09-25 | Taiwan Liposome Company (A Taiwan Corporation) | Emulsion composition comprising prostaglandin e1 |
MX2009011123A (es) * | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
EP2052716B1 (en) * | 2007-10-24 | 2014-12-31 | Camurus AB | Controlled release formulations |
WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
MX352189B (es) * | 2008-09-04 | 2017-11-10 | Amylin Pharmaceuticals Llc | Formulaciones de liberación sostenida usando portadores no acuosos. |
BR122013025625B1 (pt) | 2008-10-17 | 2021-08-03 | Sanofi-Aventis Deutschland Gmbh | Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo |
US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
US8795226B2 (en) * | 2009-06-25 | 2014-08-05 | Sanofi-Aventis Deutschland Gmbh | Cannula assembly for co-delivery of medicaments |
KR101823699B1 (ko) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
EP2496249B1 (en) * | 2009-11-03 | 2016-03-09 | Amylin Pharmaceuticals, LLC | Glp-1 receptor agonist for use in treating obstructive sleep apnea |
EP2496664B1 (de) | 2009-11-04 | 2014-10-01 | Merck Patent GmbH | Verbindungen für ein flüssigkristallines medium und deren verwendung für hochfrequenzbauteile |
SI2498801T1 (en) * | 2009-11-13 | 2018-06-29 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine |
ES2676373T3 (es) | 2009-11-13 | 2018-07-19 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
US8314080B2 (en) | 2010-04-06 | 2012-11-20 | Kuwait University | Method of treating type I diabetes |
RS55378B1 (sr) | 2010-08-30 | 2017-03-31 | Sanofi Aventis Deutschland | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
PT2714004T (pt) * | 2011-05-25 | 2024-07-12 | Camurus Ab | Formulações de peptídeos de libertação controlada |
WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
DE102011114986A1 (de) * | 2011-09-28 | 2013-03-28 | Ethris Gmbh | Sprühsystem |
US9585959B2 (en) | 2011-12-05 | 2017-03-07 | Camurus Ab | Robust controlled-release formulations |
CA2861261A1 (en) * | 2012-01-31 | 2013-08-08 | Santen Pharmaceutical Co., Ltd. | Non-aqueous liquid composition |
ES2755104T3 (es) | 2012-05-17 | 2020-04-21 | Ra Pharmaceuticals Inc | Inhibidores peptídicos y peptidomiméticos |
WO2013174978A1 (en) * | 2012-05-25 | 2013-11-28 | Camurus Ab | Somatostatin receptor agonist formulations |
EP3791861A1 (en) | 2012-07-26 | 2021-03-17 | Camurus AB | Opioid formulations |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
CN104902919B (zh) | 2012-12-21 | 2018-11-20 | 赛诺菲 | Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂 |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
RU2016132386A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
KR20160101195A (ko) | 2014-01-09 | 2016-08-24 | 사노피 | 인슐린 아스파트의 안정화된 약제학적 제형 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
SG11201608910UA (en) | 2014-04-28 | 2016-11-29 | Orphomed Inc | Buprenorphine dimer and its use in treatment of gastrointestinal disorders |
HRP20211561T8 (hr) | 2014-06-12 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulacija aktivnosti komplementa |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
LT3229828T (lt) | 2014-12-12 | 2023-06-12 | Sanofi-Aventis Deutschland Gmbh | Insulino glargino/liksisenatido fiksuoto santykio kompozicija |
WO2016123371A1 (en) | 2015-01-28 | 2016-08-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
EP3297654B1 (en) | 2015-05-22 | 2021-07-07 | The Board of Trustees of the Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with exendin(9-39) |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
SG11201804721SA (en) | 2015-12-16 | 2018-07-30 | Ra Pharmaceuticals Inc | Modulators of complement activity |
WO2017152014A1 (en) | 2016-03-04 | 2017-09-08 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
MX2018011893A (es) * | 2016-03-31 | 2019-01-10 | Sun Pharma Advanced Res Co Ltd | Gel viscoelastico de liraglutida adaptado para una administracion semanal o quincenal. |
US10954287B2 (en) | 2016-04-15 | 2021-03-23 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
WO2018060213A1 (en) | 2016-09-27 | 2018-04-05 | Camurus Ab | Formulations containing a somatostatin receptor agonist |
RU2757903C2 (ru) | 2016-09-15 | 2021-10-22 | Камурус Аб | Препараты аналогов простациклина |
US11020484B2 (en) | 2016-11-21 | 2021-06-01 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
CN108606957A (zh) * | 2016-12-13 | 2018-10-02 | 南京星银药业集团有限公司 | 一种含索马鲁肽的口服缓释制剂及其制备方法 |
IL307966A (en) | 2017-01-03 | 2023-12-01 | Intarcia Therapeutics Inc | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
EP3842061A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
EP3842449A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5340802A (en) | 1989-06-30 | 1994-08-23 | Abbott Laboratories | Peptide analog type-B CCK receptor ligands |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
BR9206593A (pt) | 1991-10-04 | 1995-11-28 | Gs Biochem Ab | Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas |
WO1993006921A1 (en) | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
JP4137179B2 (ja) | 1994-03-30 | 2008-08-20 | ジーエス ディベロップメント エービー | 生物付着性物質としての脂肪酸エステルの使用 |
SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
FR2725369B1 (fr) | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
EP0871489A1 (en) | 1995-10-12 | 1998-10-21 | Gs Development Ab | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
DK0839525T3 (da) * | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
JP2001524958A (ja) | 1997-04-17 | 2001-12-04 | ジーエス ディベロップメント アクティエボラーグ | 新規な液晶をベースとする生物接着性薬剤送出系 |
US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
EP1600162A1 (en) | 1998-12-22 | 2005-11-30 | Eli Lilly & Company | Shelf-stable formulation of glucagon-like peptide-1 |
US6467987B1 (en) * | 1999-03-29 | 2002-10-22 | Honeywell International Inc. | Resettable non-explosive actuator |
US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
US7008646B2 (en) | 2001-02-20 | 2006-03-07 | Patrick Thomas Spicer | Cubic liquid crystalline compositions and methods for their preparation |
US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
WO2003000236A1 (en) | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc | Particles with improved solubilization capacity |
JP5562510B2 (ja) * | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー/エス | 修飾glp−1の安定な処方剤 |
AU2003201998C1 (en) * | 2002-01-10 | 2012-10-25 | Imperial Innovations Limited | Modification of feeding behavior |
US7622118B2 (en) | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
DE602004017198D1 (de) | 2003-08-04 | 2008-11-27 | Camurus Ab | Verfahren zum beladen von amphiphilen teilchen mit wirkstoffen |
JP5518282B2 (ja) | 2003-09-01 | 2014-06-11 | ノヴォ ノルディスク アー/エス | 安定なペプチドの製剤 |
GB0322033D0 (en) | 2003-09-19 | 2003-10-22 | Camurus Ab | Composition |
MXPA06002941A (es) * | 2003-09-19 | 2006-05-31 | Novo Nordisk As | Derivados de enlace a albumina de peptidos terapeuticos. |
GB0325745D0 (en) * | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
EP1682091B1 (en) * | 2003-11-07 | 2017-03-29 | Camurus Ab | Compositions of lipids and cationic peptides |
WO2005063213A1 (en) | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
JP4966018B2 (ja) | 2004-01-23 | 2012-07-04 | カムルス エービー | 三元非ラメラ脂質組成物 |
RU2390331C2 (ru) | 2004-06-04 | 2010-05-27 | Камурус Аб | Жидкие депо-препараты |
WO2006013369A2 (en) | 2004-08-04 | 2006-02-09 | Camurus Ab | Compositions forming non-lamellar dispersions |
CA2594711C (en) | 2005-01-14 | 2012-11-06 | Camurus Ab | Somatostatin analogue formulations |
ES2400034T3 (es) | 2005-01-14 | 2013-04-05 | Camurus Ab | Formulaciones bioadhesivas tópicas |
EP1845942B1 (en) | 2005-01-14 | 2014-04-09 | Camurus Ab | Gnrh analogue formulations |
US8871712B2 (en) | 2005-01-14 | 2014-10-28 | Camurus Ab | Somatostatin analogue formulations |
CA2595385C (en) | 2005-01-21 | 2011-01-25 | Camurus Ab | Pharmaceutical lipid compositions |
CN101217940B (zh) | 2005-06-06 | 2013-03-27 | 卡穆鲁斯公司 | Glp-1类似物制剂 |
ES2437581T3 (es) | 2005-11-17 | 2014-01-13 | Zogenix, Inc. | Suministro de formulaciones viscosas por inyección sin aguja |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
-
2006
- 2006-06-06 CN CN2006800244885A patent/CN101217940B/zh active Active
- 2006-06-06 JP JP2008515284A patent/JP5198261B2/ja active Active
- 2006-06-06 ES ES06744133T patent/ES2399645T3/es active Active
- 2006-06-06 US US11/908,740 patent/US8546326B2/en active Active
- 2006-06-06 EP EP06744133A patent/EP1888031B1/en active Active
- 2006-06-06 WO PCT/GB2006/002079 patent/WO2006131730A1/en active Application Filing
- 2006-06-06 CA CA2609810A patent/CA2609810C/en active Active
- 2006-06-06 DK DK06744133.7T patent/DK1888031T3/da active
- 2006-06-06 PL PL06744133T patent/PL1888031T3/pl unknown
-
2007
- 2007-10-24 US US11/877,935 patent/US8097239B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2006131730A1 (en) | 2006-12-14 |
JP5198261B2 (ja) | 2013-05-15 |
EP1888031A1 (en) | 2008-02-20 |
CN101217940A (zh) | 2008-07-09 |
US8097239B2 (en) | 2012-01-17 |
US20080124394A1 (en) | 2008-05-29 |
ES2399645T3 (es) | 2013-04-02 |
CA2609810C (en) | 2012-05-22 |
DK1888031T3 (da) | 2013-02-18 |
CA2609810A1 (en) | 2006-12-14 |
US8546326B2 (en) | 2013-10-01 |
EP1888031B1 (en) | 2013-01-23 |
CN101217940B (zh) | 2013-03-27 |
US20080146490A1 (en) | 2008-06-19 |
JP2008542437A (ja) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1888031T3 (pl) | Preparaty analogu glp-1 | |
GB2424581B (en) | Formulations | |
PL1843746T3 (pl) | Formulacje analogów somatostatyny | |
EP1909584A4 (en) | PRENYLFLAVONOID FORMULATIONS | |
PL1845942T3 (pl) | Preparaty analogu GnRH | |
EP1981547A4 (en) | STABLE THERAPEUTIC FORMULATIONS | |
IL186600A0 (en) | Novel vaccine formulations | |
GB0505569D0 (en) | Formulations | |
EP1951693A4 (en) | SOLID FORMULATIONS | |
IL192149A0 (en) | Stable s-nitrosothiol formulations | |
EP1904525A4 (en) | GLP-1 PHARMACEUTICAL COMPOSITIONS | |
GB0523634D0 (en) | Solid cleaning formulations | |
GB0518878D0 (en) | Formulations | |
GB0526322D0 (en) | Formulations | |
GB0522917D0 (en) | Formulations | |
GB0520388D0 (en) | Formulations | |
GB0500912D0 (en) | Novel formulations | |
GB0522828D0 (en) | Novel formulations | |
GB0500913D0 (en) | Novel formulations | |
GB0519090D0 (en) | Novel formulations | |
GB0504106D0 (en) | Novel formulations | |
GB0500917D0 (en) | Novel formulations | |
GB0500915D0 (en) | Novel formulations | |
GB0417226D0 (en) | Formulations | |
IL179208A0 (en) | Intereferon formulations |